A Phase 1 interventional study of VEGF Trap-Eye in Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-10.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 49th largest by enrollment, is the only one that started in 2006, is one of 4 in phase 1, and was the 1st registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 1 started in 2006.
This study's enrollment of 5 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 7 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with diabetic macular edema.
This is an open label study. Initially, 5 patients with DME will receive an ITV injection of VEGF Trap into the study eye. Additional patients may be enrolled at the same or additional dose levels. Patients will be observed for six weeks following the injection for assessments of ocular and systemic safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
Drug: VEGF Trap-Eye
single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
To assess the ocular and systemic safety and tolerability of a single intravitreal (IVT) injection of VEGF Trap-Eye in patients with diabetic macular edema (DME)
Time frame: Assessments for safety and tolerablity are performed at each visit (Visit 1 - Visit 10)
To obtain a preliminary assessment of the effect of a single dose of VEGF Trap-Eye on central retinal thickness (CRT) at the center point as determined by optical coherence tomography (OCT)
Time frame: Assessments for CRT are performed at each visit (Visit 1 - Visit 10) by means of OCT.
To obtain a preliminary assessment of the effect of a single IVT administration of VEGF Trap-Eye on visual acuity
Time frame: Assessments for visual acuity are performed at each visit (Visit 1 - Visit 10).
The record gives a start of Apr 2006, a primary completion of Aug 2006 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept